Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Assets (2016 - 2025)

Karyopharm Therapeutics' Non-Current Assets history spans 14 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 33.76% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $26.2 million, up 8.39%, while the annual FY2025 figure was $5.3 million, 33.76% down from the prior year.
  • Non-Current Assets reached $5.3 million in Q4 2025 per KPTI's latest filing, down from $6.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $29.7 million in Q4 2021 to a low of $4.7 million in Q3 2024.
  • Average Non-Current Assets over 5 years is $10.0 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: tumbled 78.99% in 2021, then soared 37.39% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $29.7 million in 2021, then tumbled by 73.03% to $8.0 million in 2022, then dropped by 18.64% to $6.5 million in 2023, then grew by 22.08% to $8.0 million in 2024, then plummeted by 33.76% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Non-Current Assets are $5.3 million (Q4 2025), $6.5 million (Q3 2025), and $7.0 million (Q2 2025).